Treatment of malignant mesothelioma

World Journal of Surgery

Volumn 25, Issue 2, 2001, Pages 210-217

  Jaklitsch, Michael T ^a,b,c   Grondin, Sean C ^a,b   Sugarbaker, David J ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON A; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 2; MITOMYCIN; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE THERAPY; HUMAN; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; PHOTODYNAMIC THERAPY; PLEURA DISEASE; PLEURA TUMOR; PLEURECTOMY; RANDOMIZED CONTROLLED TRIAL;

COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; IMMUNOTHERAPY; MESOTHELIOMA; PATIENT SELECTION; PHOTOCHEMOTHERAPY; PLEURAL NEOPLASMS; PNEUMONECTOMY; QUALITY OF LIFE; RADIOTHERAPY DOSAGE;

EID: 0035048567     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002680020021     Document Type: Article

References (60)

1. Analysis of current trends in United States mesothelioma incidence
2. Benign and malignant pleural mesothelioma
3. Latent period for malignant mesothelioma of occupational origin
4. Latency periods in asbestos-related mesothelioma of the pleura
5. Cancer among spouses: Review of 195 couples
6. Mesothelioma of childhood
7. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma
8. Human mesotheliomas contain the simian virus-40 regulatory region and large tumor antigen DNA sequences
9. Simian virus 40, poliovaccines and human tumors: A review of recent developments
10. SV40 induces mesotheliomas in hamsters
11. Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates
12. Geographic patterns of pleural mesothelioma deaths in the United States, 1968-81
13. Benign and malignant mesothelioma
14. Malignant mesothelioma of the pleura: A study of 52 treated and 64 untreated patients
15. Pleural mesothelioma
16. Diffuse malignant mesothelioma: Prospective evaluation of 69 patients
17. Asbestos-related chest diseases: Plain radiographic findings
18. Computed tomographic findings of environmental asbestos-related malignant pleural mesothelioma
19. Magnetic resonance (MR) imaging of the chest: State-of-the-art
20. CT and MR in pleural disease
21. Malignant pleural mesothelioma: Value of CT and MR imaging in predicting resectability
22. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography
23. The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma
24. Pathology of malignant mesothelioma
25. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation
26. Induction chemotherapy, surgical resection and radiotherapy in patients with malignant pleural effusion, mediastinoscopy negative (stage IIIB) non-small cell lung cancer
27. Multimodality therapy for malignant mesothelioma based on a study of natural history
28. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma
29. Malignant pleural mesothelioma: Extrapleural pneumonectomy and pleurectomy
30. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
31. Late effects of cancer treatment: Radiation and drug toxicity
32. Epithelium, contractile tone, and responses to relaxing agonists in canine bronchi
33. Radiation therapy in the management of patients with mesothelioma
34. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B
35. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma
36. Chemotherapy in malignant mesothelioma: A review
37. Paclitaxel (Taxol) for malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B (CALGB 9234)
38. A phase I study of paclitaxel as a radiation sensitizer for the treatment of non-small cell lung cancer and mesothelioma
39. Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenographs in athymic nude mice
40. Extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma
41. Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma
42. Surgery and pleural space: Fibrothorax, thoracoscopy, and pleurectomy
43. The role of extrapleural pneumonectomy in malignant pleural mesothelioma: A Lung Cancer Study Group trial
44. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: Experience with 29 patients
45. Extrapleural pneumonectomy for diffuse, malignant mesothelioma
46. Moglichkeiten und ergebnisse der chirurgischen behandlung des malignen pleuramesotheliomas
47. Mesothelioma and radical multimodality therapy: Who benefits?
48. A proposed new international TNM staging system for malignant pleural mesothelioma
49. New therapies in the treatment of malignant pleural mesothelioma
50. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma
51. Potential for cytokine therapy of malignant mesothelioma
52. Effect of interferon-alpha2a on malignant mesothelioma
53. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma
54. Intrapleural administration of interleukin 2 in pleural mesothelioma: A phase I-II study
55. Patterns of recurrence and outcome for patients with stage II non-small-cell lung cancer
56. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology
57. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
58. Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy
59. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: Pharmacokinetic studies